Blood Coagulation Disorders D001778

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Blood Coagulation Disorders

Description

Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.   MeSH

Hierarchy View

View MeSH Tree View ICD-10 Tree

Subtype Terms (10)

Blood Coagulation Disorders, Inherited
1 experimental drug

Coagulation Protein Disorders
3 drugs (2 approved, 1 experimental)

Disseminated Intravascular Coagulation
12 drugs (10 approved, 2 experimental)

Ecchymosis
8 drugs (6 approved, 2 experimental)

Platelet Storage Pool Deficiency
6 approved drugs

Protein S Deficiency
 

Purpura
55 drugs (36 approved, 19 experimental)

Thrombocythemia, Essential
69 drugs (43 approved, 26 experimental)

Thromboinflammation
 

Vitamin K Deficiency
5 drugs (3 approved, 2 experimental)


Approved Indicated Drugs (1)

phylloquinone

Phase 4 Indicated Drugs (10)

antihemophilic factor viii human (Hemofil M)

blood plasma

desmopressin (ddavp)

edoxaban (savaysa)

fibrinogen (human) (RiaSTAP)

fluindione (previscan)

sintrom

unfractionated heparin

von Willebrand factor (recombinant) (Vonvendi)

warfarin (coumadin)

Phase 3 Indicated Drugs (2)

coagulation factor viia (recombinant) (NovoSevenRT)

human factor ix complex (prothrombin complex concentrate) (Bebulin)

Phase 2 Indicated Drugs (4)

crotalidae immune f(ab')2 (equine) (Anavip)

crotalidae polyvalent immune fab (ovine) (CroFab)

danazol (danocrine)

sitagliptin (januvia)

Phase 1 Indicated Drugs (3)

dabigatran (pradaxa)

tu7710

wobenzyme

Other Experimental Indicated Drugs (6)

diclofenac (voltaren)

indocyanine green (ic-green)

norethindrone

ondansetron (zofran)

palonosetron (aloxi)

tranexamic acid (cyklokapron)


Organization Involved with Phase 4 Indications (28)

Adolphe Rothschild Ophtalmologic Foundation

Canadian Hemophilia Society

Capital Medical University

CSL Behring

Dalian Medical University

Department of Health and Human Services

Florida International University

Government of Canada

Government of Nova Scotia

Harvard University

Jean Monnet University

Mountain States Regional Hemophilia Center, Aurora, Columbia

NHS Lothian

Novo Nordisk

Society for Obstetric Anesthesia and Perinatology

University of Chicago

University of Copenhagen

University of Edinburgh

University of Florida

University of Helsinki

University of Iowa

University of Ottawa

University of Sao Paulo

University of Toulouse

University of Turku

University of Zurich

Wake Forest University

Zhejiang University

Organization Involved with Phase 3 Indications (52)

Aix-University of Marseille

Asahi Kasei Pharma

Austin Health

Bataillon des marins pompiers de Marseille, France

Bayer

Biotest Pharmaceuticals

CHU Henri Mondor

Direction Centrale du Service de Santé des Armées

Ecoles militaires de santé de Lyon-Bron

Federal University of Bahia

Fire Brigade Of Paris

Floralis

French Defence Health Service

French Military

Health Research Council, New Zealand

Hebrew University

Hospital center of Annecy Genevois,France

Hospital Geral Roberto Santos

Icahn School of Medicine at Mount Sinai

Institut de Recherche Biomedicale des Armees

Johns Hopkins University

Laboratório de Investigação Médica da FMUSP

McMaster University

Medical University Innsbruck

Monash University

National Health and Medical Research Council, Australia

National Heart, Lung, and Blood Institute (NHLBI)

Pennsylvania State University

Pharmaceutical Research Associates, Inc. (PRA)

Rutgers University

Samu of Annecy, France

Samu of Lyon, France

Sungkyunkwan University

Thomas Jefferson University

TIMC-IMAG

Unity Health Toronto

University of Bielefeld

University of Colorado

University of Lille

University of Lyon

University of Minnesota

University of Modena and Reggio Emilia

University of North Carolina at Chapel Hill

University of Oregon

University of Paris

University of Pittsburgh

University of Toronto

University of Vermont

University of Washington

University of Western Ontario

University of Wisconsin

Wayne State University

Organization Involved with Phase 2 Indications (17)

Aarhus University

Assiut University

Biomarin

Catalyst Biosciences

Celularity, Inc.

Entegrion, Inc.

Gilead Sciences

Instituto Bioclon

Medical University of Vienna

Novartis

Ono Pharmaceuticals

Oriental Neurosurgery Evidence-Based-Study Team

Spark Therapeutics

Temple University

University of Arizona

University of Pennsylvania

Yale University

Organization Involved with Phase 1 Indications (7)

Dalhousie University

Imperial College London

Lee's Pharmaceutical

National Health Service, United Kingdom

Technical University of Munich

University of Montreal

Vince & Associates

Organization Involved with Other Experimental Indications (12)

Abbott

American College of Obstetricians and Gynecologists

Centers for Disease Control and Prevention (CDC)

Cornell University

Eastern Virginia Medical School

Hospital Regional de Alta especialidad de Ixtapaluca

Institute of Liver and Biliary Sciences, India

Mary M. Gooley Hemophilia Center

Seoul National University

University of Bern

University of Pretoria

University of Strasbourg

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.